Carregant...
Miniatura

Tipus de document

Article

Versió

Versió publicada

Data de publicació

Llicència de publicació

cc by (c) Franco Luzón et al., 2020
Si us plau utilitzeu sempre aquest identificador per citar o enllaçar aquest document: https://hdl.handle.net/2445/173650

Genetic and Immune Changes Associated with Disease Progression under the Pressure of Oncolytic Therapy in A Neuroblastoma Outlier Patient

Títol de la revista

Director/Tutor

ISSN de la revista

Títol del volum

Resum

Little is known about the effect of oncolytic adenovirotherapy on pediatric tumors. Here we present the clinical case of a refractory neuroblastoma that responded positively to Celyvir (ICOVIR-5 oncolytic adenovirus delivered by autologous mesenchymal stem cells) for several months. We analyzed samples during tumor evolution in order to identify molecular and mutational features that could explain the interactions between treatment and tumor and how the balance between both of them evolved. We identified a higher adaptive immune infiltration during stabilized disease compared to progression, and also a higher mutational rate and T-cell receptor (TCR) diversity during disease progression. Our results indicate an initial active role of the immune system controlling tumor growth during Celyvir therapy. The tumor eventually escaped from the control exerted by virotherapy through acquisition of resistance by the tumor microenvironment that exhausted the initial T cell response.

Matèries (anglès)

Citació

Citació

FRANCO LUZÓN, Lidia, GARCÍA MULERO, Sandra, SANZ PAMPLONA, Rebeca, MELEN, Gustavo, RUANO, David, LASSALETTA, Álvaro, MADERO, Luís, GONZÁLEZ MURILLO, África, RAMÍREZ, Manuel. Genetic and Immune Changes Associated with Disease Progression under the Pressure of Oncolytic Therapy in A Neuroblastoma Outlier Patient. _Cancers_. 2020. Vol. 12, núm. 5. [consulta: 30 de gener de 2026]. [Disponible a: https://hdl.handle.net/2445/173650]

Exportar metadades

JSON - METS

Compartir registre